China Shineway Pharmaceutical Group Ltd. is an investment holding company, which engages in the research and development, manufacturing, and trading of Chinese pharmaceutical products. The company is headquartered in Shijiazhuang, Hebei and currently employs 2,867 full-time employees. The company went IPO on 2004-12-02. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The firm operates its business in mainland China and Hong Kong markets.
China Shineway Pharmaceutical Group Limited 的关键财务报表是什么?
根据最新的财务报表(Form-10K),China Shineway Pharmaceutical Group Limited 的总资产为 $10,041,净利润为 $840
CSWYY 的关键财务比率是什么?
China Shineway Pharmaceutical Group Limited 的流动比率是 3.9,净利 margin 为 22.23,每股销售为 $5。
China Shineway Pharmaceutical Group Limited 的收入按细分市场或地理位置如何划分?
China Shineway Pharmaceutical Group Limited 最大收入来源是 Injections,在最近的收益报告中收入为 1,374,777,459。就地区而言, China including Hong Kong 是 China Shineway Pharmaceutical Group Limited 的主要市场,收入为 4,096,244,475。
China Shineway Pharmaceutical Group Limited 是否盈利?
是的,根据最新的财务报表,China Shineway Pharmaceutical Group Limited 的净利润为 $840
China Shineway Pharmaceutical Group Limited 有负债吗?
是的,China Shineway Pharmaceutical Group Limited 的负债为 2,574
China Shineway Pharmaceutical Group Limited 的流通股有多少?
China Shineway Pharmaceutical Group Limited 的总流通股为 827